A rational approach is to use tumor-localized implants loaded with tumor-specific lymphocytes that contain additional T cell-activating biologicals (such as activating anti-CD3, anti-CD28, and anti-CD137 antibodies) and T cell stimulatory cytokines (like IL-2 or IL-15). Here, IL2 is linked to neoplasm.